Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology
Post# of 421
(Total Views: 202)
Posted On: 04/01/2022 3:48:19 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Technology Continues to Showcase Ability to Improve Effectiveness of Existing Drug Brands
- Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
- Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
- The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
- Sublicensing DehydraTECH continues to create revenues for the company
- Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective
The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology.
The company recently announced it has begun animal research to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity. Epidiolex, the world’s only cannabidiol (“CBD”)-based seizure medication to gain approval from the U.S Food and Drug Administration (“FDA“) for treating epileptic conditions (https://nnw.fm/psz1f).
Lexaria has analyzed DehydraTECH-enhanced CBD in a variety of applications, the idea being that if DehydraTECH-CBD can enter the bloodstream more rapidly and more potently than CBD that hasn’t been enhanced, then Lexaria can establish the potential benefits of its IP for improving drugs trademarked by other companies.
That in turn opens the door to the possibility of high-profile brand-name drugs becoming more effective at lesser dosages, and therefore less expensive as a result. The most immediate benefits in DehydraTECH enhancement are that treated drug products are utilized by the body faster, without any troubling side effects, and that DehydraTECH’s ability to mask any unpleasant tastes eliminates the need to use sweeteners to make the drugs palatable.
The technology combines active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applies it to a target compound such as CBD, synthesizes it via a dehydration process and markets the final product as something that can be consumed or combined with a liquid or, in some applications, powders. Reduced filtration by the body’s digestive system makes the product more effective in its use.
One marked area of study announced by the company in addition to the new Epidiolex research includes human studies of DehydraTECH-CBD in reducing high blood pressure and potentially being used to treat heart disease (https://nnw.fm/sC5mu).
In non-CBD applications, the DehydraTECH technology has been studied as a means of enhancing the assimilation speed and effectiveness of orally ingested (not inhaled) nicotine, erectile dysfunction drugs such as Viagra and antiviral drugs such as Remdesivir, Ebastine and Colchicine, used in treating COVID-19 patients during the ongoing global pandemic.
Each of the research projects has reported astoundingly positive results thus far (https://nnw.fm/HM0du).
“Lexaria has a successful track record through strategic partners and licensees who use DehydraTECH technology and have demonstrated improved delivery and performance of tetrahydrocannabinol (“THC”) in both subjective human studies and marketed consumer packaged goods product offerings,” the company stated last year (https://nnw.fm/ps4eu). Lexaria has repeatedly demonstrated that DehydraTECH-processed CBD has superior delivery characteristics into the bloodstream and brain compared to generic CBD and has evidenced similar results with THC.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Health and wellness drug product innovator Lexaria Bioscience has developed a patented technology — DehydraTECH (TM) — which enhances the bioavailability of fat-soluble drugs and molecules
- Lexaria continues to research DehydraTECH’s ability to improve the speed and bioavailability of cannabidiol (“CBD”) in treating high blood pressure and epileptic conditions
- The company continues its research demonstrating the ability of its technology -to enhance the performance of antiviral drugs and other active pharmaceutical ingredients
- Sublicensing DehydraTECH continues to create revenues for the company
- Lexaria has additionally pursued the use of its drug-enhancing technology, in partnership with sublicensees, for making adult-use recreational cannabis more effective
The potential for drug innovator Lexaria Bioscience’s (NASDAQ: LEXX) patented DehydraTECH(TM) technology to transform the pharmaceutical industry continues to display itself in clinical trials and licensing deals that advance use and awareness of the technology.
The company recently announced it has begun animal research to compare effectiveness of FDA-approved Epidiolex to DehydraTECH-CBD for reducing seizure activity. Epidiolex, the world’s only cannabidiol (“CBD”)-based seizure medication to gain approval from the U.S Food and Drug Administration (“FDA“) for treating epileptic conditions (https://nnw.fm/psz1f).
Lexaria has analyzed DehydraTECH-enhanced CBD in a variety of applications, the idea being that if DehydraTECH-CBD can enter the bloodstream more rapidly and more potently than CBD that hasn’t been enhanced, then Lexaria can establish the potential benefits of its IP for improving drugs trademarked by other companies.
That in turn opens the door to the possibility of high-profile brand-name drugs becoming more effective at lesser dosages, and therefore less expensive as a result. The most immediate benefits in DehydraTECH enhancement are that treated drug products are utilized by the body faster, without any troubling side effects, and that DehydraTECH’s ability to mask any unpleasant tastes eliminates the need to use sweeteners to make the drugs palatable.
The technology combines active pharmaceutical ingredients (“APIs”) with a fatty acid oil, applies it to a target compound such as CBD, synthesizes it via a dehydration process and markets the final product as something that can be consumed or combined with a liquid or, in some applications, powders. Reduced filtration by the body’s digestive system makes the product more effective in its use.
One marked area of study announced by the company in addition to the new Epidiolex research includes human studies of DehydraTECH-CBD in reducing high blood pressure and potentially being used to treat heart disease (https://nnw.fm/sC5mu).
In non-CBD applications, the DehydraTECH technology has been studied as a means of enhancing the assimilation speed and effectiveness of orally ingested (not inhaled) nicotine, erectile dysfunction drugs such as Viagra and antiviral drugs such as Remdesivir, Ebastine and Colchicine, used in treating COVID-19 patients during the ongoing global pandemic.
Each of the research projects has reported astoundingly positive results thus far (https://nnw.fm/HM0du).
“Lexaria has a successful track record through strategic partners and licensees who use DehydraTECH technology and have demonstrated improved delivery and performance of tetrahydrocannabinol (“THC”) in both subjective human studies and marketed consumer packaged goods product offerings,” the company stated last year (https://nnw.fm/ps4eu). Lexaria has repeatedly demonstrated that DehydraTECH-processed CBD has superior delivery characteristics into the bloodstream and brain compared to generic CBD and has evidenced similar results with THC.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)